Clinical trial
A Phase I Protocol of the Combination Bortezomib and Tipifarnib for Relapsed or Refractory Multiple Myeloma
NCT00972712 is registered in ClinicalTrials.gov with Emory University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Protocol of the Combination Bortezomib and Tipifarnib for Relapsed or Refractory Multiple Myeloma
- Lead sponsor
- Emory University
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- December 31, 2006
- Completion date
- March 31, 2015
- Enrollment
- 12 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.